Skip to main content

Advertisement

Figure 4 | Journal of Hematology & Oncology

Figure 4

From: Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

Figure 4

Changes in hematologic parameters. (A) Mean (SEM) platelet counts over time. (B) Changes in individual platelet counts from baseline to nadir (left panel) and baseline to week 24 (right panel). (C) Mean (SEM) hemoglobin levels over time in patients who did not receive red blood cell transfusions during the study. SEM, standard error of mean; TDD, total daily dose.

Back to article page